Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: A phase i study

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 6, 2005, Pages 653-658

  Athanasiadis, Athanasios ^a   Roussos, George ^a   Papakostoulis, Thomas ^a   Athanasiadou, Daniela Carmen ^a   Stathopoulos, George P ^b  

^a GENERAL HOSPITAL OF LARISSA   (Greece)

^b Errikos Dunant Hospital   (Greece)

Author keywords

Gemcitabine; Non small cell lung cancer; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; PACLITAXEL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE RESPIRATORY FAILURE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ALOPECIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; OUTPATIENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SKIN TOXICITY; SUDDEN DEATH; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTPATIENTS; PACLITAXEL; SURVIVAL RATE;

EID: 26444434885     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1009-0     Document Type: Article

References (18)

1. Non-Small-Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909
2. Giaccone G (1996) New drugs for the management of lung cancer. Br J Hosp Med 55:634-638
3. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
4. Bunn-PA J, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100
5. Murphy WK, Fossella FV, Winn RJ et al (1993) A phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388
6. Gatzemeier U, Heckmayer M, Neuhauss R et al (1995) Chemotherapy of advanced inoperable non-small-cell lung cancer with paclitaxel: A phase II trial. Semin Oncol 22(6 suppl 15):24-28
7. Hainsworth JD, Thompson DS, Greco F (1995) Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609-1614
8. Anderson H, Lund B, Bach F et al (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826
9. Gatzemeier U, Sheperd FA, Le Chevalier T et al (1996) Activity of gemcitabine in patients with non-small-cell lung cancer: A multicentre extended phase II study. Eur J Cancer 32A:243-248
10. Giaccone G, Smit EF, Van Meerbeeck JPAM et al (2000) A phase I/II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients. Ann Oncol 11:109-112
11. Douillard JY, Lerouge D, Monnier A et al (2001) Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small-cell lung cancer: a multicentre phase II study. Br J Cancer 84:1179-1184
12. Isla D, Resell R, S·nchez JJ et al (2001) Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 19:1071-1077
13. Kosmidis P, Mylonakis N, Nicolaides C et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 20:3578-3585
14. Rothenberg ML, Sharma A, Weiss GR et al (1998) Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol 9:733-738
15. Gurney H, Dodwell D, Thatcher N, Tattersall MHN (1993) Escalating drug delivery in cancer chemotherapy: A review of concepts and practice - part I. Ann Oncol 4:23-34
16. Crino L, Scagliotti G, Marangolo M et al (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15:297-303
17. Crino L, Cappuzzo F (2002) Present and future treatment of advanced non-small-cell lung cancer. Semin Oncol 29(3 suppl 9):9-16
18. Cortés-Funes H (2002) New treatment approaches for lung cancer and impact on survival. Semin Oncol 29(3 suppl 8):26-29